AMP v. USPTO | GenomeWeb

AMP v. USPTO

By Turna Ray
The American Civil Liberties Union and the Public Patent Foundation have decided to ask the Supreme Court to take up their case challenging Myriad Genetics' patents on the BRCA 1 and BRCA 2 genes.

Adding large gene rearrangement analysis to Myriad's Comprehensive BRACAnalysis test could detect variants associated with increased risk for hereditary breast and ovarian cancer that occur more frequently in some populations and would otherwise be missed.

The higher court will consider whether two method patents held by Prometheus Laboratories claim natural phenomena and are therefore not patentable under the law.

Diagnostic developers and legal experts have been keeping a close watch on Prometheus since the Federal Circuit Court of Appeals' handling of diagnostic method patents in that case may impact the AMP v. USPTO gene-patenting lawsuit that is pending review by the same court.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.